Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Status:
Active, not recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting
cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a
combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can
be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them
more visible during surgery in patients with lung cancer.